BRN launches statewide notice: RNs cannot compound drugs; campaign targets med‑spa and IV‑clinic practices

The Board of Registered Nursing voted March 26, 2026, to approve an action plan directing staff to notify licensees and the public that registered nurses and (under current law) advanced practice RNs may not compound drugs in med‑spa or IV‑hydration settings and that compounding is distinct from admixing.

Executive Officer Loretta Melbby told the board complaints about compounding practices in med‑spa and IV‑hydration clinics had increased and that many nurses and APRNs did not understand the legal distinction between "admixing" (preparing medication according to the manufacturer label) and "compounding" (altering concentration, changing diluent, or mixing ingredients not on the label). "In Business and Professions Code 2725.1(b), it actually states very clearly in our statute, no registered nurse shall compound drugs," Melbby said, and staff proposed an education campaign including a list‑serve message to every licensee, social‑media posts, and a web page detailing permitted and prohibited practices.

Staff explained that admixing per package instructions — for example reconstituting a powdered drug with the labeled diluent or preparing an IV exactly as the package insert specifies — is permitted. By contrast, altering the diluent, mixing multiple products in a single bag, or otherwise departing from manufacturer directions constitutes compounding and, under current pharmacy law and BRN interpretation, must be performed by a pharmacist or physician authorized to compound. Melbby also cautioned that some outpatient businesses use fictitious supervisory arrangements or third‑party sales pitches that leave nurses vulnerable to discipline while the for‑profit organizers evade enforcement.

Public commenters urged nuance: Melanie Row (CRNA and California Association of Nurse Anesthesiology practice director) asked the board to consider incorporating the updated USP <797> immediate‑use provisions for anesthetizing locations; representatives of naturopathic and nurse‑practitioner groups asked for clarification and noted common clinical practices where nurses have historically prepared immediate‑use admixtures. Board members and staff said the campaign is intended to clarify current law and to reduce harm while state partners (notably the Board of Pharmacy) continue to maintain compounding standards and oversight.

The motion to adopt the action plan passed (roll call recorded); Vice President Neil Patel noted concerns and recorded a dissenting "no" vote. Staff said the notice and web materials will be posted in April and that staff would coordinate closely with the Board of Pharmacy to address technical questions and exceptions (for example, narrowly defined immediate‑use, life‑and‑limb‑saving scenarios authorized under pharmacy regulation and USP standards).

Next steps: Staff will distribute a list‑serve message to all licensees, publish social‑media messaging and a dedicated web page, and coordinate with the Board of Pharmacy and other healing‑arts boards on technical guidance. The board emphasized that legislative change would be required to alter the prohibition in statute; until then, the education campaign will clarify the current legal standard and reduce risks to licensees and patients.